PMID- 33288572
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 40
IP  - 12
DP  - 2020 Dec
TI  - Hypoxia-inducible Factor-1alpha Suppression in Ovarian Clear-cell Carcinoma Cells by 
      Silibinin Administration.
PG  - 6791-6798
LID - 10.21873/anticanres.14702 [doi]
AB  - BACKGROUND/AIM: Advanced ovarian clear-cell carcinoma (CCC) fails to respond to 
      standard chemotherapy, and has a poor prognosis. Since hypoxia-inducible factor-1 
      (HIF-1) stimulates various genes involved in cancer, we aimed to examine the 
      efficacy of silibinin, an active component of milk thistle belonging to 
      Asteraceae, in suppressing HIF-1 activity, and elucidate the underlying mechanism 
      in human CCC cell lines. MATERIALS AND METHODS: Human ovarian CCC cell lines 
      HAC-2, OVISE, and RMG-1 were treated with 500 muM silibinin for 4 h under normoxic 
      and hypoxic conditions. Using DNA microarray, we analysed genes whose expression 
      modulated more than 2-fold in response to hypoxia, whereas HIF-1alpha expression was 
      measured using ELISA. RESULTS: Silibinin treatment decreased HIF-1alpha protein in 
      all cell lines, and eIF4E2 and RPS6 mRNA in HAC-2 and RMG-1 cells. CONCLUSION: 
      Silibinin suppressed HIF-1alpha protein under hypoxic conditions in CCC cell lines 
      and could be a potential anti-cancer drug.
CI  - Copyright (c) 2020 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Miyazawa, Mariko
AU  - Miyazawa M
AD  - Department of Obstetrics and Gynaecology, Tokai University School of Medicine, 
      Kanagawa, Japan.
FAU - Yasuda, Masanori
AU  - Yasuda M
AD  - Department of Pathology, Saitama Medical University International Medical Centre, 
      Saitama, Japan; m_yasuda@saitama-med.ac.jp.
FAU - Miyazawa, Masaki
AU  - Miyazawa M
AD  - Department of Obstetrics and Gynaecology, Tokai University School of Medicine, 
      Kanagawa, Japan.
FAU - Ogane, Naoki
AU  - Ogane N
AD  - Department of Pathology, Kanagawa Prefectural Ashigarakami Hospital, Kanagawa, 
      Japan.
FAU - Katoh, Tomomi
AU  - Katoh T
AD  - Department of Pathology, Saitama Medical University International Medical Centre, 
      Saitama, Japan.
FAU - Yano, Mitsutake
AU  - Yano M
AD  - Department of Pathology, Saitama Medical University International Medical Centre, 
      Saitama, Japan.
AD  - Department of Obstetrics and Gynaecology, Oita University Faculty of Medicine, 
      Oita, Japan.
FAU - Hirasawa, Takeshi
AU  - Hirasawa T
AD  - Department of Obstetrics and Gynaecology, Tokai University School of Medicine, 
      Kanagawa, Japan.
FAU - Mikami, Mikio
AU  - Mikami M
AD  - Department of Obstetrics and Gynaecology, Tokai University School of Medicine, 
      Kanagawa, Japan.
FAU - Ishimoto, Hitoshi
AU  - Ishimoto H
AD  - Department of Obstetrics and Gynaecology, Tokai University School of Medicine, 
      Kanagawa, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Biomarkers)
RN  - 0 (HIF1A protein, human)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 4RKY41TBTF (Silybin)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
SB  - IM
MH  - Adenocarcinoma, Clear Cell/drug therapy/genetics/*metabolism
MH  - Antineoplastic Agents, Phytogenic/*administration & dosage
MH  - Biomarkers
MH  - Cell Hypoxia
MH  - Cell Line, Tumor
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*antagonists & inhibitors/*metabolism
MH  - L-Lactate Dehydrogenase/metabolism
MH  - Ovarian Neoplasms/drug therapy/genetics/*metabolism
MH  - Signal Transduction/drug effects
MH  - Silybin/*administration & dosage
OTO - NOTNLM
OT  - HIF-1alpha
OT  - RPS6
OT  - eIF4E
OT  - ovarian clear-cell carcinoma
OT  - silibinin
EDAT- 2020/12/09 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/12/08 05:39
PHST- 2020/10/19 00:00 [received]
PHST- 2020/11/09 00:00 [revised]
PHST- 2020/11/13 00:00 [accepted]
PHST- 2020/12/08 05:39 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 40/12/6791 [pii]
AID - 10.21873/anticanres.14702 [doi]
PST - ppublish
SO  - Anticancer Res. 2020 Dec;40(12):6791-6798. doi: 10.21873/anticanres.14702.